Navigation Links
Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease
Date:10/22/2013

ALISO VIEJO, Calif., Oct. 22, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-133. The study is a proof of concept, Phase II clinical trial investigating the use of AVP-923 for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease (PD).

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

"This is an important study of a compound with multifaceted pharmacology for the management of levodopa induced dyskinesia in Parkinson's disease," said Anthony E. Lang, MD, Professor and Director of the Division of Neurology and Chair for Parkinson's Disease Research at the University of Toronto. "Despite advances in PD therapeutics, many patients still suffer with poorly controlled dyskinesias, especially as they require higher doses of medications to increase dopamine levels. Dyskinesias can not only be disabling but may also limit the dose of effective medications that treat core symptoms of PD."

Top line data for this study is expected in the second half of calendar 2014.

About the Study

This proof-of-concept, double blind, randomized, crossover study will compare AVP-923 (45 mg of dextromethorphan / 10 mg of quinidine) with placebo for treatment of LID. The study will enroll approximately 16 PD patients across three study centers in the US and Canada. Study participants will receive, in a random order, a 2-week treatment with AVP-923 and a 2-week placebo treatment, separated by a 2-week break. At the end of each 2-week treatment period, patients will receive a 2-hour levodopa infusion to test the drug effect on dyskinesia. Patients will be carefully monitored throughout the 6-week
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
2. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
4. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
6. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
7. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
8. Avanir Pharmaceuticals to Participate in Two Conferences in August
9. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
11. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 The Board of Directors of ... provider of clinical trial imaging solutions, announced today that ... president and chief executive officer, effective immediately.  Mr. Converse ... and has held the positions of interim president and ... Dr. Charles E. Phelps , Ph.D., chairman of ...
(Date:7/23/2014)... July 23, 2014 Research and Markets ... (ECG) Market by Product, End-user & by Lead Type ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... into three major segments, namely, holter monitor, resting, and ... valued at $3,683 million in 2013 and is poised ...
(Date:7/23/2014)... July 23, 2014 On Tuesday, July ... filed suit in the 116 th Judicial ... , against RegenLab USA, LLC ("Defendant") ... Business Relationships through false and misleading actions, ... Business Disparagement through libel, disparagement, defamation, misrepresentation, ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
(Date:7/23/2014)... Home Care Assistance Calgary , North America’s ... to announce the next installment in its renowned Healthy ... of health and wellness-related fields. The upcoming webinar will ... Kriseman, and will cover the most common causes of ... more self-aware. In particular, Nancy will discuss mindfulness and ...
(Date:7/23/2014)... (HealthDay News) -- Regularly checking the pulse of a ... "Screening pulse is the method of choice for ... who have never had a stroke. Our study shows ... way to identify people who might need more thorough ... Dr. Bernd Kallmunzer, of Erlangen University in Germany. ...
(Date:7/23/2014)... Institute of Biomedical Imaging and Bioengineering will host its ... 30, 2014 on the NIH campus. There will be ... wide breadth of NIBIB-funded research. , WHO: ... Microbial Rhodopsins as Optical Voltage Sensor, Quyen Nguyen, ... for Nerve Imaging during Surgery, ...
(Date:7/23/2014)... July 23, 2014 Global Cardio Care, ... Enhanced External Counterpulsation (EECP), is celebrating the 100th ... therapy at the health center. , Weber has ... Since receiving ongoing EECP therapy since 1999, he no ... Soulati, CEO of Global Cardio Care, introduced the ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a ... other behaviors on the autistic spectrum, as well as ... of mental impairment and the most common cause of ... California, Riverside have published a study that ... FXS. Appearing online today (July 23) in the ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... The following is a,statement from the Trust for America,s ... major health crisis because the United States does not,have ... Americans are uninsured;, Tens of millions of Americans ... $2 trillion a year on medical care, more than,any ...
... have done it again!, SAN DIEGO, Dec. 14 ... Young -- The Owner,s Manual for,Extending Your Warranty, lived up ... Diet, both New York Times #1 best-sellers. Within days,of its ... and,Barnes & Noble.com. Within just a few weeks, it became ...
... Dec. 14 Following is a statement,by Linda ... Products,Association (CHPA), regarding the recommendations of the U.S. ... phenylephrine:, "Phenylephrine 10 mg is safe when ... effective for nasal decongestion in multiple clinical trials.,Today, ...
... more than 8 years of follow-up, older women taking ... Dec. 14 (HealthDay News) -- The aromatase inhibitor drug ... it comes to preventing recurrences of hormone-receptor-positive breast cancers ... was stopped, women taking Arimidex still saw a benefit, ...
... Veridex, LLC, a,Johnson & Johnson company, is pleased ... Lymph Node (BLN) Assay one of the top ten,medical ... of the magazine, available today, TIME,states: "Surgeons now have ... With GeneSearch(TM) BLN Assay, TIME goes on to say, ...
... Indiana Plan Combines Personal Responsibility and Public,Dollars, ... announced the approval of a Medicaid waiver that ... innovative health care proposal giving,approximately 120,000 low-income, uninsured ... waiver, the state will be able to begin,accepting ...
Cached Medicine News:Health News:TFAH Board of Directors Issues Statement on U.S. Health Care Crisis 2Health News:YOU: Staying Young Fourth New York Times Best-Seller for RealAge Test Creator Dr. Michael Roizen! 2Health News:Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 2Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 4Health News:HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers 2
... such as laparoscopic inguinal hernia repair ... a surgical biomaterial that enables rapid ... provides the answer to the most ... Made from strong, soft, inert and ...
... is the Bard Kugel Patch, which is constructed ... two layers create a positioning pocket, which is ... position. On the other side is a barrier ... "memory recoil ring," which causes the patch to ...
... patch repair is a minimally invasive, tension-free ... small 4-6 cm incision and requires minimal ... through an open, anterior approach that can ... Modified Kugel patch is a self-expanding polypropylene ...
... Lyra-i system combines the longest available wavelength ... maximize patient safety and efficacy. The unique ... the therapeutic range to all targeted structures. ... ensuring patient safety. All Lyra-I patients are ...
Medicine Products: